48 results on '"HAN, C."'
Search Results
2. PNS66 Stated Importance Versus Actual Impact: An Evaluation of HTA Practices to Incorporate Patient Perspectives in Value Assessments
3. PCR236 Impact of Clinical Features on Patient Reported Outcomes and Treatment Satisfaction in Psoriatic Arthritis
4. PCR93 Effect of Physicians’ Prescribing Choices of First- or Second-Line Tumor Necrosis Factor Inhibitor Biologics Versus Non-Tumor Necrosis Factor Inhibitor Biologic Therapies on Psoriatic Arthritis Patient-Reported Outcomes
5. Development and Application of a Novel Patient-Reported Outcomes Instrument, The Psoriasis Symptoms and Signs Diary, Measuring Psoriasis Severity in Clinical Trials
6. Impact of Golimumab, An Anti-Tnfα Monoclonal Antibody, On Health Related Quality of Life (Hrqol) And Work Productivity In Patients With Active Psoriatic Arthritis: 24-Week Results of The Phase Iii Go Vibrant Trial
7. Work Productivity/Interference and General Health Status Improvements with Sirukumab, an Anti-Il-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Treatment with Disease-Modifying Anti-Rheumatic Drugs: Results from the Phase 3 Sirround-D Study
8. COGNITIVE DEBRIEFING OF THE SF-36V2 WITH MODERATE-TO-SEVERE CROHN’S DISEASE PATIENTS
9. Assessment of Content Equivalence and Usability Between the Paper and Electronic Versions of the Psoriasis Symptom and Sign Diary (Pssd) Among Subjects with Plaque Psoriasis
10. PSY69 - Development and Application of a Novel Patient-Reported Outcomes Instrument, The Psoriasis Symptoms and Signs Diary, Measuring Psoriasis Severity in Clinical Trials
11. PMS66 - Impact of Golimumab, An Anti-Tnfα Monoclonal Antibody, On Health Related Quality of Life (Hrqol) And Work Productivity In Patients With Active Psoriatic Arthritis: 24-Week Results of The Phase Iii Go Vibrant Trial
12. Predictive value of patient-reported outcomes to mucosal healing in patients with moderately to severely active ulcerative colitis
13. Development Of A Patient-Reported Outcomes Measure For Psoriasis: The Psoriasis Symptoms, Signs, And Impact Questionnaire
14. PMS67 - Work Productivity/Interference and General Health Status Improvements with Sirukumab, an Anti-Il-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Treatment with Disease-Modifying Anti-Rheumatic Drugs: Results from the Phase 3 Sirround-D Study
15. Improvements in Physical Function, Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis Treated with Golimumab: Sub-Analysis of Latin American Patients Enrolled in Mulitcentre Phase III Clinical Trials
16. PGI23 - COGNITIVE DEBRIEFING OF THE SF-36V2 WITH MODERATE-TO-SEVERE CROHN’S DISEASE PATIENTS
17. Ustekinumab Improves Arthritis-Related And Skin-Related Quality Of Life In Patients With Active Psoriatic Arthritis: Patient Reported Outcomes From Randomized And Double Blinded Phase Iii Psummit I Trial
18. PMS20 Patients Reported Outcomes in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated With Golimumab: Sub-Analysis of Asia Population Enrolled in Multicentre Phase Iii Clinical Trials
19. PMS23 Health Related Quality of Life, Measured by the Short Form-36, of Patients with Rheumatoid Arthritis and Ankylosing Spondylitis in an Urban Population of China
20. PRM177 - Assessment of Content Equivalence and Usability Between the Paper and Electronic Versions of the Psoriasis Symptom and Sign Diary (Pssd) Among Subjects with Plaque Psoriasis
21. PMS48 Intravenously Administered Golimumab Significantly Improves Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis: Results of a Phase III, Placebo-Controlled Trial
22. PMS49 Fatigue is an Independent Variable Predicting Physical Function and Das-28 Remission for Patients with Rheumatoid Arthritis Treated with Intravenously Administered Golimumab: Results from a Phase 3, Placebo Controlled Clinical Trial
23. PMS52 Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Agaisnt Rheumatism: Analysis Based on Patient Reported Outcomes from 3 Phase III Clinical Trials of Golimumab
24. PMS47 EMPLOYABILITY-ADJUSTED-LIFE-YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH GOLIMUMAB PLUS METHOTREXATE OR METHOTREXATE ALONE
25. PMS66 EARLY AND SUSTAINED REMISSION ASSOCIATED WITH NORMALIZED PHYSICAL FUNCTION AND HEALTH-RELATED QUALITY OF LIFE AND SIGNIFICANTLY IMPROVED PRODUCTIVITY IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH GOLIMUMAB: TWO YEAR DATA FROM THE PHASE III GO-REVEAL CLINICAL TRIAL
26. PMS57 ASSOCIATION OF CLINICAL REMISSION AND NORMALIZED PATIENT REPORTED OUTCOMES: A VALIDATION OF TREAT-TO-TARGET FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS USING POOLED DATA FROM 3 PHASE III GOLIMUMAB CLINICAL TRIALS
27. PSY5 IMPACT OF DEPRESSION AND ANXIETY ON EMPLOYABILITY AND PRODUCTIVITY IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
28. PMS12 USTEKINUMAB RESULTS: IN RAPID, SUSTAINED AND CLINICALLY MEANINGFUL IMPROVEMENTS IN PHYSICAL DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS: FROM A RANDOMIZED AND PLACEBO-CONTROLLED PHASE II TRIAL
29. PSY42 USTEKINUMAB REDUCES ITCH, BODILY PAIN, AND FATIGUE IN PATIENTS WITH MODERATE-TO-SEVERE PSORIASIS
30. PMS29 GOLIMUMAB SIGNIFICANTLY REDUCES TIME LOST FROM WORK FOR PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED RESULTS FROM THREE PHASE 3 STUDIES
31. PMS47 GOLIMUMAB SIGNIFICANTLY IMPROVES PRODUCTIVITY IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM THE PHASE 3 GO-RAISE STUDY
32. PMS48 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROM THREE PHASE 3 STUDIES
33. PSS1 RISK OF PSYCHIATRIC DISORDERS AND HEALTH CARE EXPENDITURES AMONG PATIENTS WITH MODERATE TO SEVERE PSORIASIS
34. PMS65 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS FROMTHREE PHASE 3 STUDIES
35. PMS43 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY REDUCES TIME LOST FROM WORK FOR PATIENTS WITH RHEUMATOID ARTHRITIS: POOLED RESULTS FROMTHREE PHASE 3 STUDIES
36. PSS55 USTEKINUMAB REDUCESWORK LIMITATIONS, INCREASES WORK PRODUCTIVITY AND DECREASESWORKDAYS MISSED DUETO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
37. PSS41 USTEKINUMAB SIGNIFICANTLY IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS
38. PSS60 DERMATOLOGY LIFE QUALITY INDEX IS MORE SENSITIVE THAN PSORIASIS AREA AND SEVERITY INDEX TO MEASURE TREATMENT EFFECT IN PATIENTS WITH PSORIASIS: FINDINGS FROM THE PHOENIX I TRIAL
39. MS4 GOLIMUMAB SIGNIFICANTLY IMPROVES PRODUCTIVITY IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: RESULTS FROM THE PHASE 3 GO-RAISE STUDY
40. PMS39 LOSS OF EMPLOYABLE LIFE-YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PRELIMINARY ANALYSIS USING MARKOV MODEL
41. PGI20 MAINTENANCE THERAPY WITH INFLIXIMAB REDUCES HOSPITALIZARON AND SURGERY IN CROHN'S DISEASE
42. PSS33 - Development Of A Patient-Reported Outcomes Measure For Psoriasis: The Psoriasis Symptoms, Signs, And Impact Questionnaire
43. PGI27 - Predictive value of patient-reported outcomes to mucosal healing in patients with moderately to severely active ulcerative colitis
44. PMS19 - Improvements in Physical Function, Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis Treated with Golimumab: Sub-Analysis of Latin American Patients Enrolled in Mulitcentre Phase III Clinical Trials
45. PMS54 - Ustekinumab Improves Arthritis-Related And Skin-Related Quality Of Life In Patients With Active Psoriatic Arthritis: Patient Reported Outcomes From Randomized And Double Blinded Phase Iii Psummit I Trial
46. PMS54 Ustekinumab Improves Arthritis-Related And Skin-Related Quality Of Life In Patients With Active Psoriatic Arthritis: Patient Reported Outcomes From Randomized And Double Blinded Phase Iii Psummit I Trial
47. PGI27 Predictive value of patient-reported outcomes to mucosal healing in patients with moderately to severely active ulcerative colitis
48. PMS19 Improvements in Physical Function, Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis Treated with Golimumab: Sub-Analysis of Latin American Patients Enrolled in Mulitcentre Phase III Clinical Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.